
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6958064/publications.pdf Version: 2024-02-01



Ισηνι Μαριανί

#	Article	IF	CITATIONS
1	Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 2011, 116, 142-150.	1.6	184
2	Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder. JAMA Psychiatry, 2015, 72, 593.	6.0	131
3	Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial. Drug and Alcohol Dependence, 2014, 140, 42-47.	1.6	129
4	Quantification and comparison of marijuana smoking practices: Blunts, joints, and pipes. Drug and Alcohol Dependence, 2011, 113, 249-251.	1.6	119
5	Treatment Strategies for Co-Occurring ADHD and Substance Use Disorders. American Journal on Addictions, 2007, 16, 45-56.	1.3	116
6	A Randomized, Open-Label, Controlled Trial of Gabapentin and Phenobarbital in the Treatment of Alcohol Withdrawal. American Journal on Addictions, 2006, 15, 76-84.	1.3	80
7	Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence, 2016, 159, 53-60.	1.6	79
8	The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug and Alcohol Dependence, 2015, 154, 38-45.	1.6	78
9	Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. American Journal of Psychiatry, 2017, 174, 459-467.	4.0	76
10	New directions in the treatment of opioid withdrawal. Lancet, The, 2020, 395, 1938-1948.	6.3	72
11	Psychostimulant Treatment of Cocaine Dependence. Psychiatric Clinics of North America, 2012, 35, 425-439.	0.7	70
12	Extended-Release Mixed Amphetamine Salts and Topiramate for Cocaine Dependence: A Randomized Controlled Trial. Biological Psychiatry, 2012, 72, 950-956.	0.7	69
13	A randomized doubleâ€blind, placeboâ€controlled trial of venlafaxineâ€extended release for coâ€occurring cannabis dependence and depressive disorders. Addiction, 2013, 108, 1084-1094.	1.7	67
14	A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. American Journal of Psychiatry, 2019, 176, 129-137.	4.0	62
15	The selfâ€medication hypothesis and psychostimulant treatment of cocaine dependence: An update. American Journal on Addictions, 2014, 23, 189-193.	1.3	55
16	A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug and Alcohol Dependence, 2010, 111, 97-104.	1.6	48
17	Atomoxetine Treatment for Cocaine Abuse and Adult Attention Deficit/Hyperactivity Disorder (ADHD): A Preliminary Open Trial. Journal of Dual Diagnosis, 2009, 5, 41-56.	0.7	39
18	Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade?. Drug and Alcohol Dependence, 2013, 133, 80-85.	1.6	37

#	Article	IF	CITATIONS
19	A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. Journal of Substance Abuse Treatment, 2014, 46, 546-552.	1.5	37
20	ADHD Is Highly Prevalent in Patients Seeking Treatment for Cannabis Use Disorders. Journal of Attention Disorders, 2020, 24, 1487-1492.	1.5	36
21	A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug and Alcohol Dependence, 2011, 119, e23-e29.	1.6	35
22	Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. Drug and Alcohol Dependence, 2020, 206, 107700.	1.6	33
23	Abstinence and reduced frequency of use are associated with improvements in quality of life among treatmentâ€seekers with cannabis use disorder. American Journal on Addictions, 2018, 27, 101-107.	1.3	29
24	Assessment of riboflavin as a tracer substance: Comparison of a qualitative to a quantitative method of riboflavin measurement. Drug and Alcohol Dependence, 2013, 128, 77-82.	1.6	28
25	Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. Journal of Substance Abuse Treatment, 2008, 34, 80-89.	1.5	26
26	Antisocial Behavioral Syndromes in Cocaine and Cannabis Dependence. American Journal of Drug and Alcohol Abuse, 2008, 34, 405-414.	1.1	26
27	Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug and Alcohol Dependence, 2015, 147, 122-129.	1.6	22
28	How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. Drug and Alcohol Dependence, 2018, 188, 135-140.	1.6	21
29	Longâ€ŧerm followâ€up study of communityâ€based patients receiving XRâ€NTX for opioid use disorders. American Journal on Addictions, 2017, 26, 319-325.	1.3	20
30	Δ9-Tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug and Alcohol Dependence, 2010, 106, 65-68.	1.6	19
31	Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. American Journal of Drug and Alcohol Abuse, 2016, 42, 333-340.	1.1	19
32	Open-label pilot study of quetiapine treatment for cannabis dependence. American Journal of Drug and Alcohol Abuse, 2014, 40, 280-284.	1.1	17
33	Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users. American Journal on Addictions, 2020, 29, 345-348.	1.3	17
34	Quetiapine treatment for cannabis use disorder. Drug and Alcohol Dependence, 2021, 218, 108366.	1.6	16
35	Pharmacotherapy for Alcohol-Related Disorders: What Clinicians Should Know. Harvard Review of Psychiatry, 2004, 12, 351-366.	0.9	15
36	Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?. Drug and Alcohol Dependence, 2014, 144, 42-46.	1.6	14

#	Article	IF	CITATIONS
37	Levetiracetam for the Treatment of Co-Occurring Alcohol Dependence and Anxiety: Case Series and Review. American Journal of Drug and Alcohol Abuse, 2008, 34, 683-691.	1.1	13
38	Mixedâ€amphetamine salts increase abstinence from marijuana in patients with coâ€occurring attentionâ€deficit/hyperactivity disorder and cocaine dependence. American Journal on Addictions, 2016, 25, 666-672.	1.3	13
39	Digital Clinical Trials for Substance Use Disorders in the Age of Covid-19. Journal of Addiction Medicine, 2020, 14, e297-e302.	1.4	12
40	Drinking reduction during cognitive behavioral therapy for alcohol use disorder is associated with a reduction in anterior insulaâ€bed nucleus of the stria terminalis restingâ€state functional connectivity. Alcoholism: Clinical and Experimental Research, 2021, 45, 1596-1606.	1.4	12
41	A Comparison of Psychosocial and Cognitive Functioning Between Depressed and Non-Depressed Patients with Cannabis Dependence. Journal of Addictive Diseases, 2010, 29, 325-337.	0.8	11
42	Openâ€label trial of a singleâ€day induction onto buprenorphine extendedâ€release injection for users of heroin and fentanyl. American Journal on Addictions, 2021, 30, 470-476.	1.3	10
43	Quetiapine Treatment of Zolpidem Dependence. American Journal on Addictions, 2007, 16, 426-426.	1.3	9
44	Comparison of clinical trial recruitment populations: Treatment-seeking characteristics of opioid-, cocaine-, and cannabis-using participants. Journal of Substance Abuse Treatment, 2011, 40, 426-430.	1.5	9
45	Open-label pilot study of injectable naltrexone for cannabis dependence. American Journal of Drug and Alcohol Abuse, 2018, 44, 619-627.	1.1	9
46	Comparison of Substance Use Milestones in Cannabis- and Cocaine-Dependent Patients. Journal of Addictive Diseases, 2012, 31, 60-66.	0.8	8
47	Pilot randomized placeboâ€controlled clinical trial of highâ€dose gabapentin for alcohol use disorder. Alcoholism: Clinical and Experimental Research, 2021, 45, 1639-1652.	1.4	8
48	A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. American Journal of Drug and Alcohol Abuse, 2020, 46, 289-296.	1.1	7
49	Non-abstinent treatment outcomes for cannabis use disorder. Drug and Alcohol Dependence, 2021, 225, 108765.	1.6	7
50	Impulsiveness as a moderator of amphetamine treatment response for cocaine use disorder among ADHD patients. Drug and Alcohol Dependence, 2020, 213, 108082.	1.6	6
51	Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. Drug and Alcohol Dependence, 2021, 219, 108482.	1.6	5
52	Openâ€label pilot study of lisdexamfetamine for cocaine use disorder. American Journal of Drug and Alcohol Abuse, 2021, 47, 1-8.	1.1	5
53	Guanfacine extended-release for cannabis use disorder: a pilot feasibility trial. American Journal of Drug and Alcohol Abuse, 2020, 46, 44-48.	1.1	4
54	An adaptive clinical trial design for cocaine use disorder: Extended-release amphetamine salts for early behavioral intervention non-responders. Contemporary Clinical Trials, 2020, 98, 106187	0.8	3

#	Article	IF	CITATIONS
55	An open-label pilot study of pregabalin pharmacotherapy for alcohol use disorder. American Journal of Drug and Alcohol Abuse, 2021, 47, 467-475.	1.1	3
56	Effects of research setting on observed depressive symptoms in marijuana users. Journal of Substance Abuse Treatment, 2009, 37, 431-434.	1.5	2
57	A Case Report of Maintenance Valproic Acid Treatment Failing to Protect Against Alcohol Withdrawal. American Journal on Addictions, 2005, 14, 397-398.	1.3	0
58	Expanding Treatment Potential for Substance Use Disorders. Psychiatric Clinics of North America, 2012, 35, xiii-xiv.	0.7	0
59	Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence. JAMA Internal Medicine, 2020, 180, 162.	2.6	0
60	P42. Changes in Anterior Cingulate Cortex Activation are Associated With Improved Ability to Regulate Craving in Patients Undergoing Cognitive Behavioral Therapy for Alcohol Use Disorder. Biological Psychiatry, 2022, 91, S104-S105.	0.7	0